Analyst Consensus ?
ConsensusHold52 ratings
Bullish2344.2%
Neutral2853.9%
Bearish11.9%
Marriott International, Inc. · MAR · FY2026 Q1 · Calendar Q2 2026
Marriott Beats on RevPAR and Raises Full-Year Outlook as Luxury and Pipeline Hit Records
Marriott entered FY2026 with strong momentum, posting Q1 RevPAR growth of 4.2% that topped internal guidance and lifting full-year outlooks for both RevPAR and gross fees. The beat was led by luxury and resort segments, supported by a record global pipeline of nearly 618,000 rooms and net rooms growth of 4.5%. New brand launches (Lefay wellness), expanded AI deployments, and the upcoming FIFA World Cup provide incremental catalysts, while the Middle East conflict remains the primary headwind. Two consecutive quarters of raised guidance and a bullish score of 85 underscore management confidence.
Reported Before market openNASDAQConsumer Cyclical
$101.13B market cap
100quality score
Company context
Snapshot as of publicationMarriott International, Inc. is a leading global hospitality firm responsible for managing, franchising, and licensing a wide range of accommodation options, including hotels, residential units, and timeshare resorts, on an international scale. The company segments its extensive operations into North America (covering the U.S. and Canada) and its various international divisions. Under its corporate umbrella, Marriott oversees a diverse collection of esteemed brands, such as JW Marriott, The Ritz-Carlton, W Hotels, Sheraton, Westin, and Courtyard, among many others. As of February 15, 2022, its impressive network encompassed nearly 8,000 properties—specifically 7,989 establishments—operating across 139 countries and territories under 30 distinct hotel brand names. Established in 1927, Marriott International, Inc. maintains its corporate headquarters in Bethesda, Maryland.
Earnings scorecard
Reported versus consensus
Reported EPS
$2.72
Consensus $3
EPS surprise
+6.3%
Reported versus consensus
Reported revenue
$6.65B
Consensus $6.59B
Revenue surprise
+1.0%
Reported versus consensus
Earnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$383.52Current
$160Low
$312.27Average
$449High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Jul 29, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| TD Cowen | Buy | Buy | Maintain | Jul 21, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Jul 21, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 21, 2026 |
| Stifel | Hold | Hold | Maintain | Jul 17, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Jul 17, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Jul 16, 2026 |
| Macquarie | Neutral | Neutral | Maintain | Jul 14, 2026 |
| UBS | Neutral | Neutral | Maintain | Jun 15, 2026 |
| Truist Securities | Hold | Hold | Maintain | May 26, 2026 |
| Bernstein | Outperform | Outperform | Maintain | May 15, 2026 |
| Mizuho | Neutral | Neutral | Maintain | May 7, 2026 |
| Baird | Neutral | Neutral | Maintain | May 7, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Apr 24, 2026 |
| Susquehanna | Neutral | Neutral | Maintain | Apr 23, 2026 |
| Jefferies | Buy | Buy | Maintain | Feb 11, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Feb 11, 2026 |
| Citigroup | Neutral | Neutral | Maintain | Jan 15, 2026 |
| BMO Capital | Outperform | Market Perform | Upgrade | Jan 9, 2026 |
| Argus Research | Buy | Buy | Maintain | Jan 16, 2025 |
| B of A Securities | Buy | Buy | Maintain | Oct 21, 2024 |
| Deutsche Bank | Hold | Hold | Maintain | Aug 1, 2024 |
| Credit Suisse | Hold | Hold | Maintain | Feb 16, 2023 |
| Redburn Partners | Sell | Sell | Maintain | Nov 30, 2022 |
| Berenberg | Buy | Hold | Upgrade | Sep 15, 2022 |
| Loop Capital | Hold | Hold | Maintain | Feb 16, 2022 |
| Gordon Haskett | Hold | Hold | Maintain | Jun 26, 2020 |
| Nomura Instinet | Buy | Buy | Maintain | Jun 23, 2020 |
| Nomura | Buy | Buy | Maintain | Jun 23, 2020 |
| SunTrust Robinson Humphrey | Hold | Hold | Maintain | May 13, 2020 |
| RBC Capital | Sector Perform | Outperform | Downgrade | Mar 30, 2020 |
| CFRA | Hold | Hold | Maintain | Feb 28, 2020 |
| Stifel Nicolaus | Hold | Hold | Maintain | Feb 27, 2020 |
| Raymond James | Market Perform | Outperform | Downgrade | Jan 7, 2020 |
| Longbow Research | Neutral | Underperform | Upgrade | Jul 15, 2019 |
| Argus | Hold | Buy | Downgrade | Nov 20, 2018 |
| Cowen & Co. | Outperform | Outperform | Maintain | Oct 23, 2018 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Aug 30, 2017 |
| Guggenheim | Neutral | Neutral | Maintain | Apr 26, 2017 |
| MKM Partners | Buy | Neutral | Upgrade | Dec 5, 2016 |
| Canaccord Genuity | Buy | Buy | Maintain | Mar 23, 2016 |
| Telsey Advisory Group | Perform | Market Perform | Maintain | Jan 4, 2016 |
| Brean Capital | Hold | Hold | Maintain | Jun 25, 2015 |
| JMP Securities | Market Outperform | Market Outperform | Maintain | Feb 19, 2015 |
| FBR Capital | Outperform | Outperform | Maintain | Sep 9, 2014 |
| Bank of America | Buy | Buy | Maintain | Jan 13, 2014 |
| Oddo Securities | Neutral | Reduce | Upgrade | Jul 2, 2013 |
| ISI Group | Buy | Neutral | Upgrade | Jun 3, 2013 |
| Evercore Partners | Overweight | Overweight | Maintain | May 29, 2013 |
| Cantor Fitzgerald | Buy | Buy | Maintain | Jan 14, 2013 |
| McNicoll Lewis Vlak | Hold | Hold | Maintain | Oct 5, 2012 |
| Keefe, Bruyette & Woods | Market Perform | Outperform | Downgrade | Sep 26, 2012 |
| Keefe Bruyette & Woods | Market Perform | Outperform | Downgrade | Sep 26, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $383.52. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Barclays | Analyst unavailable | $379 | $366.24 | -1.2% | Jul 20, 2026 |
| Wells Fargo | Analyst unavailable | $449 | $369.05 | +17.1% | Jul 16, 2026 |
| Bernstein | Analyst unavailable | $412 | $402.79 | +7.4% | Jun 15, 2026 |
| UBS | Analyst unavailable | $412 | $402.54 | +7.4% | Jun 15, 2026 |
| Bernstein | Analyst unavailable | $402 | $353.47 | +4.8% | May 15, 2026 |
| Morgan Stanley | Analyst unavailable | $353 | $354.77 | -8.0% | May 12, 2026 |
| Wells Fargo | Analyst unavailable | $446 | $355.54 | +16.3% | May 7, 2026 |
| Argus Research | John Staszak | $425 | $354.67 | +10.8% | May 7, 2026 |
| Deutsche Bank | Steven Pizzella | $376 | $354.87 | -2.0% | May 7, 2026 |
| Mizuho Securities | Analyst unavailable | $384 | $359.06 | +0.1% | May 7, 2026 |
| Robert W. Baird | Analyst unavailable | $386 | $359.06 | +0.6% | May 7, 2026 |
| Barclays | Analyst unavailable | $376 | $359.06 | -2.0% | May 7, 2026 |
| Evercore ISI | Analyst unavailable | $400 | $367.08 | +4.3% | Apr 24, 2026 |
| Susquehanna | Christopher Stathoulopoulos | $385 | $367.13 | +0.4% | Apr 23, 2026 |
| Barclays | Analyst unavailable | $372 | $363.74 | -3.0% | Apr 16, 2026 |
| Morgan Stanley | Analyst unavailable | $350 | $354.2 | -8.7% | Apr 10, 2026 |
| Truist Financial | Patrick Scholes | $350 | $366.67 | -8.7% | Feb 11, 2026 |
| Evercore ISI | Analyst unavailable | $385 | $366.5 | +0.4% | Feb 11, 2026 |
| Mizuho Securities | Ben Chaiken | $343 | $359.35 | -10.6% | Feb 11, 2026 |
| Goldman Sachs | Lizzie Dove | $398 | $358.15 | +3.8% | Feb 11, 2026 |
| Robert W. Baird | Analyst unavailable | $358 | $359.35 | -6.7% | Feb 11, 2026 |
| BMO Capital | Analyst unavailable | $400 | $359.35 | +4.3% | Feb 10, 2026 |
| Evercore ISI | Analyst unavailable | $350 | $320.56 | -8.7% | Jan 22, 2026 |
| Morgan Stanley | Stephen Grambling | $328 | $325.79 | -14.5% | Jan 16, 2026 |
| Barclays | Brandt Montour | $320 | $325.79 | -16.6% | Jan 16, 2026 |
| BMO Capital | Analyst unavailable | $370 | $324.91 | -3.5% | Jan 9, 2026 |
| Bernstein | Analyst unavailable | $369 | $314.95 | -3.8% | Jan 6, 2026 |
| Barclays | Analyst unavailable | $276 | $305.97 | -28.0% | Dec 17, 2025 |
| Goldman Sachs | Lizzie Dove | $345 | $298.78 | -10.0% | Dec 15, 2025 |
| Truist Financial | Patrick Scholes | $283 | $306.65 | -26.2% | Dec 4, 2025 |
| Goldman Sachs | Analyst unavailable | $288 | $281.86 | -24.9% | Nov 5, 2025 |
| Barclays | Brandt Montour | $274 | $272.24 | -28.6% | Nov 5, 2025 |
| Morgan Stanley | Stephen Grambling | $296 | $268.43 | -22.8% | Oct 22, 2025 |
| Barclays | Brandt Montour | $262 | $266.4 | -31.7% | Oct 3, 2025 |
| Argus Research | Analyst unavailable | $310 | $261.8 | -19.2% | Sep 18, 2025 |
| Bernstein | Analyst unavailable | $327 | $262.05 | -14.7% | Sep 17, 2025 |
| Truist Financial | Patrick Scholes | $278 | $265.07 | -27.5% | Sep 3, 2025 |
| Susquehanna | Christopher Stathoulopoulos | $280 | $273.23 | -27.0% | May 16, 2025 |
| Morgan Stanley | Analyst unavailable | $298 | $270.8 | -22.3% | Mar 4, 2025 |
| Evercore ISI | Duane Pfennigwerth | $330 | $290.75 | -14.0% | Feb 4, 2025 |
| Wells Fargo | Daniel Politzer | $285 | $290.75 | -25.7% | Feb 4, 2025 |
| Robert W. Baird | Michael Bellisario | $285 | $290.46 | -25.7% | Feb 3, 2025 |
| BMO Capital | Ari Klein | $265 | $259.66 | -30.9% | Nov 5, 2024 |
| Robert W. Baird | Michael Bellisario | $264 | $259.53 | -31.2% | Nov 5, 2024 |
| Mizuho Securities | Ben Chaiken | $246 | $259.66 | -35.9% | Nov 5, 2024 |
| Goldman Sachs | Lizzie Dove | $280 | $259.66 | -27.0% | Nov 5, 2024 |
| BMO Capital | Ari Klein | $255 | $264.97 | -33.5% | Oct 22, 2024 |
| Robert W. Baird | Michael Bellisario | $258 | $262.57 | -32.7% | Oct 17, 2024 |
| Bank of America Securities | Shaun Kelley | $275 | $253.04 | -28.3% | Sep 27, 2024 |
| Goldman Sachs | Lizzie Dove | $267 | $235.61 | -30.4% | Sep 18, 2024 |
| Bernstein | Richard Clarke | $262 | $231.37 | -31.7% | Aug 29, 2024 |
| Wells Fargo | Daniel Politzer | $238 | $216.12 | -37.9% | Aug 1, 2024 |
| Barclays | Brandt Montour | $240 | $227.3 | -37.4% | Aug 1, 2024 |
| Mizuho Securities | Ben Chaiken | $260 | $237.41 | -32.2% | Apr 23, 2024 |
| Mizuho Securities | Ben Chaiken | $263 | $252.11 | -31.4% | Mar 25, 2024 |
| Morgan Stanley | Stephen W Grambling | $225 | $191.62 | -41.3% | Sep 26, 2023 |
| Jefferies | Analyst unavailable | $184 | $174.96 | -52.0% | Feb 3, 2023 |
| Truist Financial | Analyst unavailable | $205 | $161.44 | -46.5% | Nov 15, 2022 |
| Barclays | Brandt Montour | $170 | $164.07 | -55.7% | Aug 15, 2022 |
| Argus Research | John Staszak | $203 | $154.02 | -47.1% | May 19, 2022 |
| BMO Capital | Ari Klein | $183 | $178.19 | -52.3% | May 5, 2022 |
| Stifel Nicolaus | Simon Yarmak | $180 | $179.38 | -53.1% | May 4, 2022 |
| Morgan Stanley | Analyst unavailable | $182 | $176.28 | -52.5% | May 2, 2022 |
| Truist Financial | Patrick Scholes | $182 | $174.92 | -52.5% | Feb 20, 2022 |
| Morgan Stanley | Thomas Allen | $172 | $183.26 | -55.2% | Feb 16, 2022 |
| Wells Fargo | Dori Kesten | $199 | $181.2 | -48.1% | Feb 15, 2022 |
| Cowen & Co. | Kevin Kopelman | $180 | $156.53 | -53.1% | Dec 7, 2021 |
| Evercore ISI | Steve Sakwa | $160 | $155.02 | -58.3% | Oct 19, 2021 |
Track every rating change on MAR the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session close
Stock move
+1.3%
Event window
SPY move
+1.4%
Same window
Abnormal move
-0.1%
Stock minus SPY
Volume
1.4×
Versus trailing sessions
Subsequent drift
+7.3%
Up to 20 sessions
MARSPY benchmark
Follow MAR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Global RevPAR rose 4.2% in Q1, exceeding top-end guidance on luxury and resort strength. Full-year RevPAR guidance raised to 2-3% from 1.5-2.5%. EPS of $2.72 beat consensus of $2.56 by 6.25%; revenue of $6.654B topped estimates by 1.03%. Record global pipeline of nearly 618,000 rooms with conversions accounting for 35% of signings. Introduced Lefay, Marriott's first dedicated luxury wellness brand. Capex outlook increased to $1.05-$1.15B.
Guidance delta
Raised for the second consecutive quarter. Full-year RevPAR growth lifted to 2-3% from 1.5-2.5%. Gross fee guidance increased to $5.93-$5.99B. Net rooms growth target of 4.5-5% reiterated. Capex outlook increased to $1.05-$1.15B for Lefay, digital, and renovations.
Key takeaways
- Q1 RevPAR exceeded guidance with luxury and resort segments leading growth.
- Full-year RevPAR guidance raised to 2-3%; gross fee guidance lifted to $5.93-$5.99B.
- Record pipeline of nearly 618,000 rooms supports 4.5-5% net rooms growth target.
- AI investments accelerating: conversational search on marriott.com, 1,000th hotel transitioned to new tech ecosystem.
- World Cup expected to add 30-35 bps to RevPAR as official hotel supporter in all 16 host cities.
Management priorities
- Launch Lefay luxury wellness brand later in 2026.
- Expand Series by Marriott into Italy and the United Kingdom.
- Deploy conversational search on marriott.com and mobile app by Q2.
- Roll out AI tools across sales, marketing, and guest communications.
- Invest $1.05-$1.15B in capex on Lefay, digital, and renovations.
- Renegotiate co-branded credit card agreements with Visa, Chase, and Amex.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:12.209961+00:00
- Polygon adjusted daily market bars · 2026-07-29T02:12:15.757915+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-29T02:12:15.755213+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.